ClinicalTrials.gg
CompletedNCT00393484Updated Nov 26, 2014Results posted

A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

A Phase 4 interventional study of Entecavir and Lamivudine Placebo in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 15 sites in Korea, Republic of. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2014-11-26.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
26th of 61
122 · median 109
Started
2007
with 6 others
Phase 4
33 of 64
2 open now
Registered
6th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 26th largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 4, and was the 6th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis B DNA, \<300 copies/mL, by Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction assay) that is comparable (noninferior) and potentially superior to lamivudine, 100 mg once daily, in adults with hepatitis B e antigen-negative chronic hepatitis B virus infection.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Nucleoside and nucleotide-naive subjects with chronic infection
  • Hepatitis B Surface antigen(HBsAg)-positive ≥6 months
  • Detectable HBsAg
  • HBV DNA ≥ 105 copies/mL by PCR
  • 1.3 to 10 x the
  • HBeAg negative, anti-hepatitis B Virus E antigen antibody (anti-HBeAb) positive status
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Arm A

    Entecavir + Lamivudine placebo (0-96 weeks) Entecavir (96-240 weeks)

    Drug: Entecavir · Drug: Lamivudine Placebo

  • Active comparator
    Arm B

    Lamivudine + Entecavir placebo (0-96 weeks) Lamivudine (96-240 weeks)

    Drug: Lamivudine · Drug: Entecavir Placebo

Interventions

  • Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)

    Also known as: Baraclude, BMS-200475

  • DrugLamivudine Placebo

    Capsules, Oral, 0 mg, once daily (0-96 weeks)

  • Capsules, Oral, 100 mg, once daily (0-96 weeks) Tablets, Oral, 100 mg, once daily (96-240 weeks)

  • DrugEntecavir Placebo

    Tablets, Oral, 0 mg, once daily (0-96 weeks)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Virologic Response at Week 24

    Virologic response=Hepatitis B virus DNA \<300 copies/mL by polymerase chain reaction assay.

    Time frame: At Week 24

Secondary outcomes

  1. Number of Participants With Hepatitis B Virus (HBV) DNA <10^3, <10^4, or < 10^5 Copies/mL by Polymerase Chain Reaction (PCR) Assy at Weeks 24, 48, and 96

    The number and percentage of participants achieving the following endpoints will be tabulated at each visit through Week 240 by treatment group: HBV DNA \<300 copies/mL by PCR assay; HBV DNA \<10\^3, \<10\^4, or \< 10\^5 copies/mL by PCR assay. Treatment comparisons will be assessed using the same method as the primary endpoint.

    Time frame: At Weeks 24, 48, and 96

  2. Mean Log10 Reduction From Baseline in Hepatitis B Virus (HBV) DNA at Weeks 24, 48, 96, 144, 192, and 240

    Mean log10 reduction from Baseline in HBV DNA virus by the Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction (PCR) assay at Week 24. The extent of the decrease was estimated by comparing HBV DNA levels of all participants in each group with a linear regression model with covariates of treatment and baseline HBV DNA by PCR assay.

    Time frame: At Weeks 24, 48, 96, 144, 192, and 240

  3. Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24

    Mean ALT values from baseline by laboratory test. .

    Time frame: At Week 24

  4. Number of Participants With Normalization of Serum Alanine Aminotransferase (ALT) Levels at Weeks 24, 48, and 96

    Normalization of serum ALT= ≤\*institutional upper limit of normal.

    Time frame: At Weeks 24, 48, and 96

  5. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 24

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Most common AEs=AEs affecting ≥3 participants. Grade 3 (Severe)/Grade 4 (Very Severe)AEs per World Health Organization (WHO) criteria.Serious adverse events/deaths reported for enrolled patients regardless of treatment status.

    Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period

  6. Number of Participants With Elevations in Alanine Transaminase (ALT) and Aspartate Aminoaminase (AST) Levels, Elevations in ALT and AST Levels,Simultaneous Elevations in ALT and Total Bilirubin Levels, and ALT Flares at Week 24

    ALT flares=ALT\>2\*Baseline and 10\*upper limit of normal. Serious adverse events/deaths reported for enrolled patients regardless of treatment status.

    Time frame: Start of dosing (Day 1) until end of treatment (24 weeks) + 5 days and to end of 24-week follow-up period

  7. Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 24

    ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).

    Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to the end of the 24-week follow-up period

  8. Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24

    Vital signs assessed included blood pressure, heart rate, body temperature, and respiration rate.

    Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period

  9. Number of Participants With Virologic Rebound at Week 24

    Virologic rebound was defined as a confirmed ≥1 log10 increase in hepatitis B virus (HBV) DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA measurements or last on-treatment measurement).

    Time frame: At Week 24

  10. Percentage of Participants With a Virologic Response as Defined by Undetectable Hepatitis B Virus DNA at Weeks 48, 96, 144, 192, and 240

    Undetectable HBV DNA= \<300 copies/mL by polymerase chain reaction assay

    Time frame: At Weeks 48, 96, 144, 192, and 240

  11. Number of Participants With Viral Rebound and Drug-resistant Hepatitis B Virus (HBV) DNA Mutations at Week 96

    Virologic rebound was defined as a confirmed ≥1 log10 increase in HBV DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA values or last on-treatment measurement).

    Time frame: At 96 weeks

  12. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 240

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Start of dosing (Day 1) until end of treatment (Week 240) + 5 days

  13. Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 96

    ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).

    Time frame: Start of dosing (Day 1) until Week 96

07

Results

Posted Nov 18, 2010

Participant flow

Double-blind Period (Day 1 to Week 96)
Participant flow — Double-blind Period (Day 1 to Week 96)
MilestoneEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Started5664
Participants excluded from analysis11
Completed5452
Not completed212
Withdrew: Adverse event01
Withdrew: Withdrawal by subject20
Withdrew: No longer met inclusion criteria03
Withdrew: Lack of efficacy06
Withdrew: Lost to follow-up02
Open-label Period (Weeks 96 to 240)
Participant flow — Open-label Period (Weeks 96 to 240)
MilestoneEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Started4844
Withdrew consent66
Lack of efficacy02
Completed4021
Not completed823
Withdrew: Withdrawal by subject41
Withdrew: Death10
Withdrew: Lost to follow-up12
Withdrew: Noncompliance22
Withdrew: Lack of efficacy018

Outcome measures

PrimaryPercentage of Participants Who Achieved a Virologic Response at Week 24

Virologic response=Hepatitis B virus DNA \<300 copies/mL by polymerase chain reaction assay.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Virologic Response at Week 24
Percentage of participantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Percentage of Participants Who Achieved a Virologic Response at Week 2492.8667.19
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0006 (There was no adjustment for the prior test of noninferiority because the test for superiority could succeed only if noninferiority was first established.) · Difference in proportion: 25.67 · 90% CI 14.48 to 36.86
SecondaryNumber of Participants With Hepatitis B Virus (HBV) DNA <10^3, <10^4, or < 10^5 Copies/mL by Polymerase Chain Reaction (PCR) Assy at Weeks 24, 48, and 96

The number and percentage of participants achieving the following endpoints will be tabulated at each visit through Week 240 by treatment group: HBV DNA \<300 copies/mL by PCR assay; HBV DNA \<10\^3, \<10\^4, or \< 10\^5 copies/mL by PCR assay. Treatment comparisons will be assessed using the same method as the primary endpoint.

Time frame:
At Weeks 24, 48, and 96
Reported as:
Number · Participants
Number of Participants With Hepatitis B Virus (HBV) DNA <10^3, <10^4, or < 10^5 Copies/mL by Polymerase Chain Reaction (PCR) Assy at Weeks 24, 48, and 96
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Week 24: HBV DNA <10^35446
Week 24: HBV DNA <10^45453
Week 24: HBV DNA <10^55459
Week 48: HBV DNA <10^35445
Week 48: HBV DNA <10^45550
Week 48: HBV DNA <10^55552
Week 96: HBV DNA <10^35338
Week 96: HBV DNA <10^45342
Week 96: HBV DNA <10^55345
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0003 (Treatment comparisons were assessed using the same method used in the primary endpoint.) · Difference: 24.55 · 90% CI 14.45 to 34.66
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0167 (Treatment comparisons were assessed using the same method as the primary endpoint.) · Difference: 13.62 · 90% CI 4.85 to 22.38
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.4467 · Mean difference (final values): 4.24 · 90% CI -2.62 to 11.10
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0002 · Difference: 26.12 · 90% CI 15.87 to 36.36
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0009 · Difference: 20.09 · 90% CI 11.10 to 29.07
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0029 · Difference: 16.96 · 90% CI 8.43 to 25.50
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 35.27 · 90% CI 24.02 to 46.51
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 29.02 · 90% CI 18.07 to 39.97
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0006 · Difference: 24.33 · 90% CI 13.71 to 34.95
SecondaryMean Log10 Reduction From Baseline in Hepatitis B Virus (HBV) DNA at Weeks 24, 48, 96, 144, 192, and 240

Mean log10 reduction from Baseline in HBV DNA virus by the Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction (PCR) assay at Week 24. The extent of the decrease was estimated by comparing HBV DNA levels of all participants in each group with a linear regression model with covariates of treatment and baseline HBV DNA by PCR assay.

Time frame:
At Weeks 24, 48, 96, 144, 192, and 240
Reported as:
Mean · log10 copies/mL
Mean Log10 Reduction From Baseline in Hepatitis B Virus (HBV) DNA at Weeks 24, 48, 96, 144, 192, and 240
log10 copies/mLEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg+ Placebo
At 24 Weeks3.58 ± 0.602.95 ± 0.69
At 48 Weeks3.56 ± 0.532.65 ± 0.61
At 96 Weeks3.59 ± 0.522.42 ± 0.60
At 144 Weeks-3.60 ± 0.60-2.74 ± 0.70
At 192 Weeks-3.60 ± 0.63-2.75 ± 0.73
At 240 Weeks-3.53 ± 0.85-2.69 ± 0.98
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariates of treatment and baseline hepatitis B DNA by PCR.)
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariants of treatment and Baseline hepatitis B DNA by PCR.)
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariants of treatment and Baseline hepatitis B DNA by PCR.)
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariants of treatment and Baseline hepatitis B DNA by PCR.)
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariants of treatment and Baseline hepatitis B DNA by PCR.)
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg+ Placebo · unpaired t-test · p = <0.0001 (Treatment comparisons were based on 2-sided t-test for treatment difference (entecavir: lamivudine) estimated from the linear regression model with covariants of treatment and Baseline hepatitis B DNA by PCR.)
SecondaryMean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24

Mean ALT values from baseline by laboratory test. .

Time frame:
At Week 24
Reported as:
Mean · U/L
Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24
U/LEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 2431.5 ± 14.0443.26 ± 32.08
SecondaryNumber of Participants With Normalization of Serum Alanine Aminotransferase (ALT) Levels at Weeks 24, 48, and 96

Normalization of serum ALT= ≤\*institutional upper limit of normal.

Time frame:
At Weeks 24, 48, and 96
Reported as:
Number · Participants
Number of Participants With Normalization of Serum Alanine Aminotransferase (ALT) Levels at Weeks 24, 48, and 96
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
At 24 Weeks4337
At 48 Weeks4838
At 96 Weeks4933
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0278 · Difference: 18.97 · 90% CI 5.22 to 32.73At 24 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0014 · Difference: 26.34 · 90% CI 13.65 to 39.03At 48 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 35.94 · 90% CI 23.35 to 48.52At 96 Weeks
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 24

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Most common AEs=AEs affecting ≥3 participants. Grade 3 (Severe)/Grade 4 (Very Severe)AEs per World Health Organization (WHO) criteria.Serious adverse events/deaths reported for enrolled patients regardless of treatment status.

Time frame:
Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 24
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Deaths00
SAEs03
Discontinuations Due to AEs01
Any AEs1423
Most common AEs: Upper Respiratory Infection37
Most common AEs: Nasopharyngitis14
Most common AEs: Urticaria03
WHO Grade 3/4 AEs00
SecondaryNumber of Participants With Elevations in Alanine Transaminase (ALT) and Aspartate Aminoaminase (AST) Levels, Elevations in ALT and AST Levels,Simultaneous Elevations in ALT and Total Bilirubin Levels, and ALT Flares at Week 24

ALT flares=ALT\>2\*Baseline and 10\*upper limit of normal. Serious adverse events/deaths reported for enrolled patients regardless of treatment status.

Time frame:
Start of dosing (Day 1) until end of treatment (24 weeks) + 5 days and to end of 24-week follow-up period
Reported as:
Number · Participants
Number of Participants With Elevations in Alanine Transaminase (ALT) and Aspartate Aminoaminase (AST) Levels, Elevations in ALT and AST Levels,Simultaneous Elevations in ALT and Total Bilirubin Levels, and ALT Flares at Week 24
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
ALT elevations >2*Baseline (BL)01
AST elevations >2*BL01
ALT elevations >3*BL & AST elevations >2*BL01
Simultaneous ALT & Total bilirubin elevation00
ALT flares00
SecondaryNumber of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 24

ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).

Time frame:
Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to the end of the 24-week follow-up period
Reported as:
Number · Participants
Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 24
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Gr 4 Prothrombin time (>3*ULN)10
Gr 3 Glucose (251-500 mg/dL)12
Gr 3 ALT (5.1-10*ULN)01
Gr 3 Lipase (2.0-5.0*ULN)01
SecondaryNumber of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24

Vital signs assessed included blood pressure, heart rate, body temperature, and respiration rate.

Time frame:
Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period
Reported as:
Number · Participants
Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 2400
SecondaryNumber of Participants With Virologic Rebound at Week 24

Virologic rebound was defined as a confirmed ≥1 log10 increase in hepatitis B virus (HBV) DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA measurements or last on-treatment measurement).

Time frame:
At Week 24
Reported as:
Number · Participants
Number of Participants With Virologic Rebound at Week 24
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg
Number of Participants With Virologic Rebound at Week 2403
SecondaryPercentage of Participants With a Virologic Response as Defined by Undetectable Hepatitis B Virus DNA at Weeks 48, 96, 144, 192, and 240

Undetectable HBV DNA= \<300 copies/mL by polymerase chain reaction assay

Time frame:
At Weeks 48, 96, 144, 192, and 240
Reported as:
Number · Percetage of participants
Percentage of Participants With a Virologic Response as Defined by Undetectable Hepatitis B Virus DNA at Weeks 48, 96, 144, 192, and 240
Percetage of participantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
At 48 Weeks94.6460.94
At 96 Weeks94.6448.44
At 144 Weeks67.8634.38
At 192 Weeks69.6425.00
At 240 Weeks67.8615.63
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 33.71 · 90% CI 22.52 to 44.89At 48 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Mean difference (final values): 46.21 · 90% CI 34.80 to 57.61At 96 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = 0.0003 · Difference: 33.48 · 90% CI 19.31 to 47.65At 144 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 44.64 · 90% CI 31.17 to 58.11At 192 Weeks
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001 · Difference: 52.23 · 90% CI 39.54 to 64.93At 240 Weeks
SecondaryNumber of Participants With Viral Rebound and Drug-resistant Hepatitis B Virus (HBV) DNA Mutations at Week 96

Virologic rebound was defined as a confirmed ≥1 log10 increase in HBV DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA values or last on-treatment measurement).

Time frame:
At 96 weeks
Reported as:
Number · Participants
Number of Participants With Viral Rebound and Drug-resistant Hepatitis B Virus (HBV) DNA Mutations at Week 96
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Viral rebound126
Drug-resistant mutations013
Statistical analysis
  • Entecavir, 0.5 mg + Placebo vs Lamivudine, 100 mg + Placebo · Chi-squared · p = <0.0001
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 240

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Start of dosing (Day 1) until end of treatment (Week 240) + 5 days
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 240
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
SAEs717
Discontinuations due to AEs01
Any nonserious AEs4849
Nonserious AEs related to study conditions16
SAEs related to study conditions00
SecondaryNumber of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 96

ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).

Time frame:
Start of dosing (Day 1) until Week 96
Reported as:
Number · Participants
Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 96
ParticipantsEntecavir, 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Platelets11
Prothrombin time10
Neutrophils01
AST03
ALT06
Total bilirubiin13
Creatinine20
Lipase24
Potassium01
Glucose, fasting32

Adverse events

Collected over Start of dosing (Day 1) until end of treatment (Week 240) + 5 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entecavir , 0.5 mg + Placebo—7/56 (12.5%)28/56 (50%)
Lamivudine, 100 mg + Placebo—17/64 (26.6%)29/64 (45.3%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventEntecavir , 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Subdural hemorrhageInjury, poisoning and procedural complications2/560/64
Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/561/64
Liposarcoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/560/64
Blood glucose increasedInvestigations1/560/64
Gallbladder polypHepatobiliary disorders1/561/64
Rib fractureInjury, poisoning and procedural complications1/561/64
Tibia fractureMusculoskeletal and connective tissue disorders1/560/64
HydrocephalusNervous system disorders1/560/64
Optic neuropathyEye disorders1/560/64
Subarachnoid hemorrhageNervous system disorders1/560/64
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEntecavir , 0.5 mg + PlaceboLamivudine, 100 mg + Placebo
Upper respiratory tract infectionInfections and infestations9/5612/64
NasopharyngitisInfections and infestations6/566/64
FatigueGeneral disorders5/566/64
GastritisGastrointestinal disorders5/562/64
Reflux esophagitisGastrointestinal disorders3/562/64
DyspepsiaGastrointestinal disorders3/562/64
Colonic polypGastrointestinal disorders0/563/64
InsomniaPsychiatric disorders2/563/64
Blood glucose increasedInvestigations0/563/64
Dermatitis, contactSkin and subcutaneous tissue disorders1/563/64

Baseline characteristics

All participants who received study drug

Age, Continuous
Age, Continuous(years)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
Mean45.73 ± 11.9348.98 ± 7.8447.46 ± 10.05
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
Female91625
Male474895
Region of Enrollment
Region of Enrollment(participants)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
Korea, Republic of5664120
Prior interferon treatment status
Prior interferon treatment status(Participants)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
No5464118
Yes202
Hepatitis B virus DNA by polymerase chain reaction
Hepatitis B virus DNA by polymerase chain reaction(log10 copies/mL)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
Mean6.06 ± 0.785.79 ± 0.905.91 ± 0.86
Alanine aminotransferase
Alanine aminotransferase(U/L)Entecavir, 0.5 mg + PlaceboLamivudine, 100 mg + PlaceboTotal
Mean110.46 ± 81.9793.94 ± 58.46101.65 ± 70.59
08

Study locations

15 sites
  • Local Institution
    Bucheon, 420-717, Korea, Republic of
  • Local Institution
    Busan, 602-739, Korea, Republic of
  • Local Institution
    Chuncheon, 200-704, Korea, Republic of
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Daegu, 705-030, Korea, Republic of
  • Local Institution
    Daejeon, 301-721, Korea, Republic of
  • Local Institution
    Guri, 471-020, Korea, Republic of
  • Local Institution
    Jeonju, 561-180, Korea, Republic of
  • Local Institution
    Seoul, 130-702, Korea, Republic of
  • Local Institution
    Seoul, 135-270, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 136-705, Korea, Republic of
  • Local Institution
    Seoul, 138-040, Korea, Republic of
  • Local Institution
    Seoul, 150-950, Korea, Republic of
  • Local Institution
    Seoul, 152-050, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2006
First posted
Oct 27, 2006
Start
Feb 2007
Primary completionActual
Jan 2009
CompletionActual
Sep 2013
Results first posted
Nov 18, 2010
Last update
Nov 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00393484
Responsible party
Sponsor
First posted
Oct 27, 2006
Start date
Feb 2007
Primary completion
Jan 2009
Completion
Sep 2013
Results posted
Nov 18, 2010
Last update
Nov 26, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion